BCG Vaccine clinical trials
Also written BCG.
Related medicines add 1 study
Counted the way a researcher would: BCG Vaccine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses BCG Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BCG Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Jun 1989 · N/A · BLA 103050 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
102 studies that test it; most in 2020 (14)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1997 | 1 |
| 1999 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 5 |
| 2019 | 5 |
| 2020 | 14 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 88
University of Oxford (8) · Bandim Health Project (8) · Massachusetts General Hospital (6) · Radboud University Medical Center (5) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (4) · Memorial Sloan Kettering Cancer Center (3) · ImmunityBio, Inc. (3) · Murdoch Childrens Research Institute (3)
Often tested with
Tested in the same studies.
Gemcitabine (8) · Nogapendekin alfa inbakicept (3) · Docetaxel (2) · Durvalumab (2) · Sasanlimab (1) · Tremelimumab (1) · Atezolizumab (1) · Measles-Mumps-Rubella Vaccine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
BCG Vaccine is the comparator. A study of two new drugs counts under both.
- 1Mtbvac · Biofabri, S.L · next primary completion Feb 2029
Reaching primary completion within a year · 7
Studies that test BCG Vaccine.
- Nov 2026Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerPhase 2 · ImmunityBio, Inc.
- Dec 2026NORTH-REG Dwell-Time StudyPhase 4 · Jørgen Bjerggaard Jensen
- Jul 2027A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.Phase 1/2 · Queen's University
- Aug 2027Diabetes Diagnosis, Management, Prevention and Education in Guinea-BissauPhase 4 · Bandim Health Project
- Oct 2027Antibiotics and Vaccine Immune Responses StudyPhase 4 · South Australian Health and Medical Research Institute
- Nov 2027Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG TreatmentPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Evaluating the Safety and Immunogenicity of MTBVACPhase 2 · HIV Vaccine Trials Network
Studies
Open first, then newest update. How each study uses BCG Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 103
- Evaluating the Safety and Immunogenicity of MTBVACRecruitingPhase 2HIV Vaccine Trials NetworkNCT05947890Written as BCG
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06833073Written as BCG
- Antibiotics and Vaccine Immune Responses StudyRecruitingPhase 4South Australian Health and Medical Research InstituteNCT06148025Written as BCG vaccine
- DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBCRecruitingPhase 3Fudan UniversityNCT07207824Written as Active Comparator: BCG induction and maintenance
- Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)RecruitingPhase 3Verity Pharmaceuticals Inc.NCT05037279Written as Bacillus Calmette-Guerin: Strain Russian BCG-I
- Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingPhase 2ImmunityBio, Inc.NCT06829823Written as N-803 and BCG
- A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.Not yet recruitingPhase 1/2Queen's UniversityNCT07064863Written as Gemcitabine + BCG
- BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in AfricaEnrolling by invitationPhase 4Bandim Health ProjectNCT07005726Written as BCG Vaccine
- Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?Enrolling by invitationEarly Phase 1Tamir Ben-HurNCT06078891Written as BCG vaccine
- Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized StudyRecruitingNot applicableAl-Azhar UniversityNCT05626101Written as BCG
- Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)RecruitingPhase 3Chengdu CoenBiotech Co., LtdNCT06241755Written as BCG for Therapeutic Use
- Measles and BCG Vaccines for Mother and ChildRecruitingPhase 4Bandim Health ProjectNCT04899765Written as BCG vaccine
- A Controlled Human Infection Model (CHIM) With Intradermal BCG in MalawiNot yet recruitingNot applicableLiverpool School of Tropical MedicineNCT06178666Written as BCG
- Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without NephroureterectomyNot yet recruitingPhase 2Shaheen AlaneeNCT03345134Written as MK-3475 and BCG
- Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBCCompletedPhase 4Assiut UniversityNCT05701332Written as Bacillus Calmette Guerin
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingPhase 3PfizerNCT04165317Written as Bacillus Calmette-Guerin
- Intravesical BCG vs GEMDOCE in NMIBCActive, not recruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05538663Written as Bacillus Calmette Guerin
- Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South AfricaWithdrawnPhase 1/2International Maternal Pediatric Adolescent AIDS Clinical Trials GroupNCT05539989Written as BCG Vaccine
- BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingPhase 3AstraZenecaNCT05943106Written as BCG
- Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG TreatmentActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT04179162Written as Bacillus Calmette-Guérin (BCG)
See all 103 studies that test BCG Vaccine →
Given beside what is tested · 32 — BCG Vaccine is usual care or a partner of the new treatment
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerRecruitingPhase 1PfizerNCT07206225Written as BCG
- ID93/GLA-SE Vaccination + BCG ChallengeRecruitingNot applicableUniversity of OxfordNCT06670755Written as BCG Danish
- A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07726992Written as SHR-1501+BCG
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07424287Written as BCG for Injection
- A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerRecruitingPhase 1/2Suzhou Forlong Biotechnology Co., LtdNCT07122414Written as FL115+BCG
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBCRecruitingPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06186414Written as SIM0237 and BCG
- Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder CancerNot yet recruitingPhase 4Ruijin HospitalNCT05580354Written as BCG combined with Tislelizumab
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT03711032Written as BCG
- Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder CancerActive, not recruitingPhase 2Fudan UniversityNCT06187506Written as Bacillus Calmette Guerin Vaccine
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03504163Written as Bacillus Calmette-Guérin (BCG)
- Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerActive, not recruitingPhase 3AstraZenecaNCT03528694Written as Bacillus Calmette-Guerin (BCG)
- First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10bActive, not recruitingPhase 1Statens Serum InstitutNCT06050356Written as BCG
- Phase I Open Label BCG Clinical Trial Assessing TB Drugs and VaccinesCompletedPhase 1Fred Hutchinson Cancer CenterNCT05592223Written as BCG Vaccine USP
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingPhase 2/3ImmunityBio, Inc.NCT03022825Written as N-803 and BCG
- A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedPhase 3Bristol-Myers SquibbNCT04149574Written as Bacillus Calmette-Guérin (BCG)
- Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedPhase 2National Cancer Institute (NCI)NCT02015104Written as BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
- Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsActive, not recruitingPhase 3UNICANCERNCT03799835Written as BCG
- BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder CancerTerminatedPhase 3NCIC Clinical Trials GroupNCT00352079Written as BCG vaccine
- Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder CancerActive, not recruitingPhase 3University of SydneyNCT02948543Written as Bacillus of Calmette-Guerin (BCG)
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedPhase 2Bristol-Myers SquibbNCT03519256Written as BCG
Showing 20 of 32.
As the comparator · 19 — what is tested is compared with BCG Vaccine
- The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder CancerNot yet recruitingNot applicableAssiut UniversityNCT07873333Written as BCG
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaRecruitingPhase 3Biofabri, S.LNCT04975178Written as BCG
- Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder CancerRecruitingPhase 3Turku University HospitalNCT03664869Written as BCG instillation therapy
- Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African NeonatesCompletedPhase 2Biofabri, S.LNCT03536117Written as BCG
- MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South AfricaCompletedPhase 1/2International AIDS Vaccine InitiativeNCT02933281Written as BCG
- Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of BladderCompletedPhase 2Cadila PharnmaceuticalsNCT00694915Written as BCG (Bacillus Calmette-Guerin)
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy AdolescentsCompletedPhase 1AerasNCT02378207Written as BCG
- Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy AdolescentsCompletedPhase 2AerasNCT02075203Written as Bacillus Calmette-Guérin (BCG)
- Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in AdultsCompletedPhase 1/2Biofabri, S.LNCT02729571Written as BCG
- Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South AfricaCompletedPhase 2Serum Institute of India Pvt. Ltd.NCT02391415Written as BCG
- Phase I Trial of DAR-901CompletedPhase 1Dartmouth-Hitchcock Medical CenterNCT02063555Written as BCG
- SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study IWithdrawnPhase 3Medical Enterprises Europe B.V.NCT02254915Written as Bacillus Calmette-Guérin
- Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder CancerTerminatedPhase 3Medical Enterprises Europe B.V.NCT00384891Written as Bacillus Calmette-Guérin
- First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBCWithdrawnPhase 3Bioniche Life Sciences Inc.NCT01284205Written as Bacillus Calmette-Guerin
- Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South AfricaCompletedPhase 2Vakzine Projekt Management GmbHNCT01479972Written as BCG
- Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder CancerCompletedPhase 3University of Rome Tor VergataNCT01442519Written as bacillus Calmette-Guerin
- Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)Status unknownPhase 3Urological Oncology Council of Northern TokyoNCT01082510Written as Bacille Calmette-Guerin
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male VolunteersCompletedPhase 1Vakzine Projekt Management GmbHNCT00749034Written as BCG
- Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder CancerCompletedPhase 1/2University Of PerugiaNCT00696579Written as BCG
Codes
What other systems call BCG Vaccine · ClinicalTrials.gg INT007047
- MeSH (NLM) D001500BCG VaccineConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 8VJE55B0VGBACILLUS CALMETTE-GUERIN LIVE ANTIGEN, UNSPECIFIED SUBSTRAINConfirmed FDA, Wikidata
- Wikidata Q798309BCG vaccineConfirmed FDA, Wikidata
- DrugBank DB12768One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001500 | BCG Vaccine | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 8VJE55B0VG | BACILLUS CALMETTE-GUERIN LIVE ANTIGEN, UNSPECIFIED SUBSTRAIN | Confirmed FDA, Wikidata |
| Wikidata | Q798309 | BCG vaccine | Confirmed FDA, Wikidata |
| DrugBank | DB12768 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.